

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Apr 08 "Ask CAS" for self-help around the clock
NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4 Apr 09 ZDB will be removed from STN
NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER
NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available
NEWS 9 Jun 03 New e-mail delivery for search results now available
NEWS 10 Jun 10 MEDLINE Reload
NEWS 11 Jun 10 PCTFULL has been reloaded
NEWS 12 Jul 02 FOREGE no longer contains STANDARDS file segment
NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;
saved answer sets no longer valid
NEWS 14 Jul 29 Enhanced polymer searching in REGISTRY
NEWS 15 Jul 30 NETFIRST to be removed from STN
NEWS 16 Aug 08 CANCERLIT reload
NEWS 17 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18 Aug 08 NTIS has been reloaded and enhanced
NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)
now available on STN
NEWS 20 Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21 Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22 Aug 26 Sequence searching in REGISTRY enhanced
NEWS 23 Sep 03 JAPIO has been reloaded and enhanced
NEWS 24 Sep 16 Experimental properties added to the REGISTRY file
NEWS 25 Sep 16 CA Section Thesaurus available in CAPLUS and CA
NEWS 26 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985
NEWS 27 Oct 21 EVENTLINE has been reloaded
NEWS 28 Oct 24 BEILSTEIN adds new search fields
NEWS 29 Oct 24 Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 30 Oct 25 MEDLINE SDI run of October 8, 2002
NEWS 31 Nov 18 DKILIT has been renamed APOLLIT
NEWS 32 Nov 25 More calculated properties added to REGISTRY
NEWS 33 Dec 02 TIBKAT will be removed from STN
NEWS 34 Dec 04 CSA files on STN
NEWS 35 Dec 17 PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 36 Dec 17 TOXCENTER enhanced with additional content
NEWS 37 Dec 17 Adis Clinical Trials Insight now available on STN
NEWS 38 Dec 30 ISMEC no longer available
NEWS 39 Jan 21 NUTRACEUT offering one free connect hour in February 2003
NEWS 40 Jan 21 PHARMAML offering one free connect hour in February 2003
NEWS 41 Jan 29 Simultaneous left and right truncation added to COMPENDEX,
ENERGY, INSPEC
NEWS 42 Feb 13 CANCERLIT is no longer being updated
NEWS 43 Feb 24 METADEX enhancements
NEWS 44 Feb 24 PCTGEN now available on STN
NEWS 45 Feb 24 TEMA now available on STN
NEWS 46 Feb 26 NTIS now allows simultaneous left and right truncation
NEWS 47 Feb 26 PCTFULL now contains images
NEWS 48 Mar 04 SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 49 Mar 19 APOLLIT offering free connect time in April 2003
NEWS 50 Mar 20 EVENTLINE will be removed from STN
NEWS 51 Mar 24 PATDPAFULL now available on STN
NEWS 52 Mar 24 Additional information for trade-named substances without
structures available in REGISTRY
NEWS 53 Mar 24 Indexing from 1957 to 1966 added to records in CA/CAPLUS

NEWS EXPRESS January 6 CURRENT WINDOWS VERSION IS V6.01a,
CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS INTER General Internet Information
 NEWS LOGIN Welcome Banner and News Items
 NEWS PHONE Direct Dial and Telecommunication Network Access to STN
 NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:56:27 ON 31 MAR 2003

=> FIL BIOSIS, CABA, CAPLUS, EMBASE, LIFESCI, MEDLINE, SCISEARCH, USPATFULL, JAPIO		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'BIOSIS' ENTERED AT 13:56:38 ON 31 MAR 2003
 COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'CABA' ENTERED AT 13:56:38 ON 31 MAR 2003
 COPYRIGHT (C) 2003 CAB INTERNATIONAL (CABI)

FILE 'CAPLUS' ENTERED AT 13:56:38 ON 31 MAR 2003
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 13:56:38 ON 31 MAR 2003
 COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'LIFESCI' ENTERED AT 13:56:38 ON 31 MAR 2003
 COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'MEDLINE' ENTERED AT 13:56:38 ON 31 MAR 2003

FILE 'SCISEARCH' ENTERED AT 13:56:38 ON 31 MAR 2003
 COPYRIGHT (C) 2003 Institute for Scientific Information (ISI) (R)

FILE 'USPATFULL' ENTERED AT 13:56:38 ON 31 MAR 2003
 CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'JAPIO' ENTERED AT 13:56:38 ON 31 MAR 2003
 COPYRIGHT (C) 2003 Japanese Patent Office (JPO) - JAPIO

=> s Choi, ?/AU
 ADDITIONAL CHARACTERS REQUIRED AFTER '?' FOR LEFT TRUNCATION
 Additional characters must follow the left truncation symbol in your search term. If your search term contains a punctuation mark before the truncation symbol and you are searching in a field that uses implied proximity, the system may interpret the truncation symbol as being at the beginning of a term. Implied proximity is used in search fields indexed as single words, for example, the Basic Index. To see which fields in the current file have left truncation, enter "HELP"

SFIELDS" at an arrow prompt (=>).

=> s Choi, ?/AU

ADDITIONAL CHARACTERS REQUIRED AFTER '?' FOR LEFT TRUNCATION
Additional characters must follow the left truncation symbol in your search term. If your search term contains a punctuation mark before the truncation symbol and you are searching in a field that uses implied proximity, the system may interpret the truncation symbol as being at the beginning of a term. Implied proximity is used in search fields indexed as single words, for example, the Basic Index. To see which fields in the current file have left truncation, enter "HELP SFIELDS" at an arrow prompt (=>).

=> s Choi, ?/AU

ADDITIONAL CHARACTERS REQUIRED AFTER '?' FOR LEFT TRUNCATION
Additional characters must follow the left truncation symbol in your search term. If your search term contains a punctuation mark before the truncation symbol and you are searching in a field that uses implied proximity, the system may interpret the truncation symbol as being at the beginning of a term. Implied proximity is used in search fields indexed as single words, for example, the Basic Index. To see which fields in the current file have left truncation, enter "HELP SFIELDS" at an arrow prompt (=>).

=> s Choi/AU

L1 710 CHOI/AU

=> s l1 and pneumoniae

L2 0 L1 AND PNEUMONIAE

=> s l1 and Streptococcus

L3 0 L1 AND STREPTOCOCCUS

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	18.78	18.99

FILE 'BIOSIS' ENTERED AT 13:58:41 ON 31 MAR 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'CABA' ENTERED AT 13:58:41 ON 31 MAR 2003
COPYRIGHT (C) 2003 CAB INTERNATIONAL (CABI)

FILE 'CAPLUS' ENTERED AT 13:58:41 ON 31 MAR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 13:58:41 ON 31 MAR 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'LIFESCI' ENTERED AT 13:58:41 ON 31 MAR 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'MEDLINE' ENTERED AT 13:58:41 ON 31 MAR 2003

FILE 'SCISEARCH' ENTERED AT 13:58:41 ON 31 MAR 2003
COPYRIGHT (C) 2003 Institute for Scientific Information (ISI) (R)

FILE 'USPATFULL' ENTERED AT 13:58:41 ON 31 MAR 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'JAPIO' ENTERED AT 13:58:41 ON 31 MAR 2003
COPYRIGHT (C) 2003 Japanese Patent Office (JPO) - JAPIO

=> s streptococcus
L4 274956 STREPTOCOCCUS

=> s pneumoniae
L5 152179 PNEUMONIAE

=> s l4 and l5
L6 79185 L4 AND L5

=> s vaccine?
L7 460043 VACCINE?

=> s l6 and l7
L8 10083 L6 AND L7

=> s Choi and l8
L9 23 CHOI AND L8

=> dup rem l9
PROCESSING COMPLETED FOR L9
L10 23 DUP REM L9 (0 DUPLICATES REMOVED)

=> d ab bib l10 1-23

L10 ANSWER 1 OF 23 USPATFULL

AB The invention is directed to improved animal feed compositions comprising one or more milk proteins produced in the seeds of a transgenic plant and methods of making and using the same.

AN 2003:80313 USPATFULL

TI Feed additive compositions and methods

IN Huang, Ning, Davis, CA, UNITED STATES

Rodriguez, Raymond L., Davis, CA, UNITED STATES

Hagie, Frank E., Sacramento, CA, UNITED STATES

PI US 2003056244 A1 20030320

AI US 2002-76816 A1 20020214 (10)

RLI Continuation-in-part of Ser. No. US 2001-847232, filed on 2 May 2001, PENDING

PRAI WO 2001-US14234 20011108

US 2001-269188P 20010214 (60)

US 2001-266929P 20010206 (60)

US 2000-201182P 20000502 (60)

DT Utility

FS APPLICATION

LREP PERKINS COIE LLP, P.O. BOX 2168, MENLO PARK, CA, 94026

CLMN Number of Claims: 37

ECL Exemplary Claim: 1

DRWN 45 Drawing Page(s)

LN.CNT 5847

L10 ANSWER 2 OF 23 USPATFULL

AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods

and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

AN 2003:57430 USPATFULL
TI Nucleic acids, proteins, and antibodies
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PA Human Genome Sciences, Inc., Rockville, MD (U.S. corporation)
PI US 2003039994 A1 20030227
AI US 2002-91526 A1 20020307 (10)
RLI Continuation of Ser. No. US 2001-764889, filed on 17 Jan 2001, PENDING
PRAI US 2000-179065P 20000131 (60)
US 2000-180628P 20000204 (60)
US 2000-214886P 20000628 (60)
US 2000-217487P 20000711 (60)
US 2000-225758P 20000814 (60)
US 2000-220963P 20000726 (60)
US 2000-217496P 20000711 (60)
US 2000-225447P 20000814 (60)
US 2000-218290P 20000714 (60)
US 2000-225757P 20000814 (60)
US 2000-226868P 20000822 (60)
US 2000-216647P 20000707 (60)
US 2000-225267P 20000814 (60)
US 2000-216880P 20000707 (60)
US 2000-225270P 20000814 (60)
US 2000-251869P 20001208 (60)
US 2000-235834P 20000927 (60)
US 2000-234274P 20000921 (60)
US 2000-234223P 20000921 (60)
US 2000-228924P 20000830 (60)
US 2000-224518P 20000814 (60)
US 2000-236369P 20000929 (60)
US 2000-224519P 20000814 (60)
US 2000-220964P 20000726 (60)
US 2000-241809P 20001020 (60)
US 2000-249299P 20001117 (60)
US 2000-236327P 20000929 (60)
US 2000-241785P 20001020 (60)
US 2000-244617P 20001101 (60)
US 2000-225268P 20000814 (60)
US 2000-236368P 20000929 (60)
US 2000-251856P 20001208 (60)
US 2000-251868P 20001208 (60)
US 2000-229344P 20000901 (60)
US 2000-234997P 20000925 (60)
US 2000-229343P 20000901 (60)
US 2000-229345P 20000901 (60)
US 2000-229287P 20000901 (60)
US 2000-229513P 20000905 (60)
US 2000-231413P 20000908 (60)
US 2000-229509P 20000905 (60)
US 2000-236367P 20000929 (60)
US 2000-237039P 20001002 (60)
US 2000-237038P 20001002 (60)
US 2000-236370P 20000929 (60)
US 2000-236802P 20001002 (60)
US 2000-237037P 20001002 (60)
US 2000-237040P 20001002 (60)
US 2000-240960P 20001020 (60)
US 2000-239935P 20001013 (60)
US 2000-239937P 20001013 (60)
US 2000-241787P 20001020 (60)
US 2000-246474P 20001108 (60)

US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)

US 2000-251030P 20001205 (60)
 US 2000-251479P 20001206 (60)
 US 2000-256719P 20001205 (60)
 US 2000-250160P 20001201 (60)
 US 2000-251989P 20001208 (60)
 US 2000-250391P 20001201 (60)
 US 2000-254097P 20001211 (60)
 US 2000-231968P 20000912 (60)
 US 2000-226279P 20000818 (60)
 US 2000-186350P 20000302 (60)
 US 2000-184664P 20000224 (60)
 US 2000-189874P 20000316 (60)
 US 2000-198123P 20000418 (60)
 US 2000-227009P 20000823 (60)
 US 2000-235484P 20000926 (60)
 US 2000-190076P 20000317 (60)
 US 2000-209467P 20000607 (60)
 US 2000-205515P 20000519 (60)
 US 2001-259678P 20010105 (60)

DT Utility

FS APPLICATION

LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850

CLMN Number of Claims: 24

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 17529

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 3 OF 23 USPATFULL

AB Glycosylated polypeptides comprising the primary structure
 NH.sub.2--X--Pp--COOH, wherein X is a peptide addition comprising or
 contributing to a glycosylation site, and Pp is a polypeptide of
 interest or comprising the primary structure NH.sub.2-P.sub.x--X--
 P.sub.y-COOH, wherein P.sub.x is an N-terminal part of a polypeptide Pp
 of interest, P.sub.y is a C-terminal part of said polypeptide Pp, and X
 is a peptide addition comprising or contributing to a glycosylation site
 are provided. The glycosylated polypeptides possess improved properties
 as compared to the polypeptide of interest.

AN 2003:51224 USPATFULL

TI Peptide extended glycosylated polypeptides

IN Okkels, Jens Sigurd, Vedbaek, DENMARK

Jensen, Anne Dam, Copenhagen, DENMARK

van den Hazel, Bart, Copenhagen, DENMARK

PI US 2003036181 A1 20030220

AI US 2001-896896 A1 20010629 (9)

PRAI DK 2000-1027 20000630

DK 2000-1092 20000714

WO 2000-DK743 20001229

WO 2001-DK90 20010209

US 2000-217497P 20000711 (60)

US 2000-225558P 20000816 (60)

DT Utility

FS APPLICATION

LREP MAXYGEN, INC., 515 GALVESTON DRIVE, RED WOOD CITY, CA, 94063

CLMN Number of Claims: 57

ECL Exemplary Claim: 1

DRWN 2 Drawing Page(s)

LN.CNT 4732

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 4 OF 23 USPATFULL

AB This invention is directed to antigen library immunization, which
 provides methods for obtaining antigens having improved properties for
 therapeutic and other uses. The methods are useful for obtaining

improved antigens that can induce an immune response against pathogens, cancer, and other conditions, as well as antigens that are effective in modulating allergy, inflammatory and autoimmune diseases.

AN 2002:344432 USPATFULL
TI ANTIGEN LIBRARY IMMUNIZATION
IN PUNNONEN, JUHA, PALO ALTO, CA, UNITED STATES
BASS, STEVEN H., HILLSBOROUGH, CA, UNITED STATES
WHALEN, ROBERT GERALD, PARIS, FRANCE
HOWARD, RUSSELL, LOS ALTOS HILLS, CA, UNITED STATES
STEMMER, WILLEM P. C., LOS GATOS, CA, UNITED STATES
PI US 2002198162 A1 20021226
AI US 1999-247890 A1 19990210 (9)
PRAI US 1998-74294P 19980211 (60)
US 1998-105509P 19981023 (60)
DT Utility
FS APPLICATION
LREP MAXYGEN, INC., 515 GALVESTON DRIVE, RED WOOD CITY, CA, 94063
CLMN Number of Claims: 53
ECL Exemplary Claim: 1
DRWN 21 Drawing Page(s)
LN.CNT 5366
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 5 OF 23 USPATFULL

AB The present invention relates to novel human serine protease polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human serine protease polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human serine protease polypeptides.

AN 2002:343975 USPATFULL
TI Serine protease polynucleotides, polypeptides, and antibodies
IN Shi, Yanggu, Gaithersburg, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Ni, Jian, Germantown, MD, UNITED STATES
PA Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)
PI US 2002197701 A1 20021226
AI US 2002-67761 A1 20020208 (10)
RLI Continuation of Ser. No. US 2001-804156, filed on 13 Mar 2001, PENDING
PRAI US 2000-189025P 20000314 (60)
DT Utility
FS APPLICATION
LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 13077
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 6 OF 23 USPATFULL

AB The present invention relates to novel human serine protease polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human serine protease polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human serine protease polypeptides.

AN 2002:337440 USPATFULL
TI Serine proteases
IN Ni, Jian, Germantown, MD, UNITED STATES
Shi, Yanggu, Gaithersburg, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES

PA Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)

PI US 2002192800 A1 20021219

AI US 2002-125459 A1 20020419 (10)

RLI Continuation of Ser. No. US 2001-946633, filed on 6 Sep 2001, PENDING
Continuation of Ser. No. US 2000-597839, filed on 20 Jun 2000, ABANDONED
Continuation-in-part of Ser. No. WO 2000-US12207, filed on 5 May 2000, UNKNOWN
Continuation-in-part of Ser. No. WO 2000-US12207, filed on 5 May 2000, UNKNOWN

PRAI US 1999-133239P 19990507 (60)
US 1999-135163P 19990520 (60)
US 1999-147005P 19990803 (60)
US 1999-152935P 19990909 (60)
US 1999-162979P 19991101 (60)

DT Utility

FS APPLICATION

LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850

CLMN Number of Claims: 22

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 8818

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 7 OF 23 USPATFULL

AB The present invention relates to novel human serine protease polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human serine protease polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human serine protease polypeptides.

AN 2002:221783 USPATFULL

TI Serine proteases

IN Ni, Jian, Germantown, MD, UNITED STATES

Shi, Yanggu, Gaithersburg, MD, UNITED STATES

Ruben, Steven M., Olney, MD, UNITED STATES

PA Human Genome Sciences, Inc., Rockville, MD (U.S. corporation)

PI US 2002119925 A1 20020829

AI US 2001-946633 A1 20010906 (9)

RLI Continuation-in-part of Ser. No. WO 2000-US12207, filed on 5 May 2000, UNKNOWN
Continuation-in-part of Ser. No. WO 2000-US16848, filed on 20 Jun 2000, UNKNOWN
Continuation of Ser. No. US 2000-597839, filed on 20 Jun 2000, PENDING

PRAI US 1999-133239P 19990507 (60)

US

US

US

US

US 1999-133239P 19990507 (60)

US 1999-135163P 19990520 (60)

US 1999-147005P 19990803 (60)

US 1999-152935P 19990909 (60)

US 1999-162979P 19991101 (60)

DT Utility

FS APPLICATION

LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850

CLMN Number of Claims: 21

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 8813

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 8 OF 23 USPATFULL

AB The present invention relates a novel antimicrobial peptide HBD-3 and

derivatives thereof as well as the gene encoding the peptide. The invention further relates to methods of use of the HBD-3 peptide including a method of inhibiting microbial growth by administering an effective amount of the HBD-3 peptide alone or in combination with other antimicrobial agents or antibiotics. In addition, the immunomodulatory properties of the HBD-3 peptide also facilitate the manipulation of the immune response, i.e., as a chemoattractant for immature dendritic cells or memory T cells.

AN 2002:214215 USPATFULL
TI Human beta-defensin-3 (HBD-3), a highly cationic beta-defensin antimicrobial peptide
IN McCray, Paul B., JR., Iowa City, IA, UNITED STATES
Tack, Brian F., Iowa City, IA, UNITED STATES
Jia, Hong Peng, Iowa City, IA, UNITED STATES
Schutte, Brian C., Iowa City, IA, UNITED STATES
PI US 2002115602 A1 20020822
AI US 2001-872852 A1 20010601 (9)
PRAI US 2000-208792P 20000601 (60)
DT Utility
FS APPLICATION
LREP Steven L. Highlander, Fulbright & Jaworski L.L.P., Suite 2400, 600 Congress Avenue, Austin, TX, 78701
CLMN Number of Claims: 55
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 3851
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 9 OF 23 USPATFULL

AB The present invention relates to novel respiratory system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "respiratory system antigens," and the use of such respiratory system antigens for detecting disorders of the respiratory system, particularly the presence of cancer of respiratory system tissues and cancer metastases. More specifically, isolated respiratory system associated nucleic acid molecules are provided encoding novel respiratory system associated polypeptides. Novel respiratory system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human respiratory system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the respiratory system, including cancer of respiratory system tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

AN 2002:165194 USPATFULL
TI Nucleic acids, proteins, and antibodies
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PI US 2002086823 A1 20020704
AI US 2001-764889 A1 20010117 (9)
PRAI US 2000-179065P 20000131 (60)
DT Utility
FS APPLICATION
LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 17471

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 10 OF 23 USPATFULL

AB The present invention relates to novel human serine protease polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human serine protease polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human serine protease polypeptides.

AN 2002:133469 USPATFULL

TI Serine protease polynucleotides, polypeptides, and antibodies

IN Shi, Yanggu, Gaithersburg, MD, UNITED STATES

Ruben, Steven M., Olney, MD, UNITED STATES

Ni, Jian, Germantown, MD, UNITED STATES

PI US 2002068320 A1 20020606

AI US 2001-804156 A1 20010313 (9)

PRAI US 2000-189025P 20000314 (60)

DT Utility

FS APPLICATION

LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850

CLMN Number of Claims: 22

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 13119

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 11 OF 23 USPATFULL

AB An isolated and purified outer membrane protein of a Moraxella strain, particularly M. catarrhalis, having a molecular mass of about 200 kDa, is provided. The about 200 kDa outer membrane protein as well as nucleic acid molecules encoding the same are useful in diagnostic applications and immunogenic compositions, particularly for in vivo administration to a host to confer protection against disease caused by a bacterial pathogen that produces the about 200 kDa outer membrane protein or produces a protein capable of inducing antibodies in a host specifically reactive with the about 200 kDa outer membrane protein.

AN 2002:133221 USPATFULL

TI HIGH MOLECULAR WEIGHT MAJOR OUTER MEMBRANE PROTEIN OF MORAXELLA

IN SASAKI, KEN, WILLOWDALE, CANADA

HARKNESS, ROBIN E., WILLOWDALE, CANADA

LOOSMORE, SHEENA M., AURORA, CANADA

CHONG, PELE, RICHMOND HILL, CANADA

KLEIN, MICHEL H., WILLOWDALE, CANADA

PI US 2002068070 A1 20020606

US 6440425 B2 20020827

AI US 1996-621944 A1 19960326 (8)

DT Utility

FS APPLICATION

LREP SIM AND MCBURNEY, SUITE 701, 330 UNIVERSITY AVENUE, TORONTO, M5G1R7

CLMN Number of Claims: 37

ECL Exemplary Claim: 1

DRWN 25 Drawing Page(s)

LN.CNT 1685

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 12 OF 23 USPATFULL

AB The present invention relates to human stanniocalcin (STC) polynucleotides, polypeptides, and other Stanniocalcin compositions and to novel methods based thereon. In a specific embodiment, the Stanniocalcin compositions of the invention are used to treat or protect neural cells. Moreover, the present invention relates to vectors, host cells, antibodies, and recombinant and synthetic methods for producing the Stanniocalcin compositions of the invention. Also provided are

diagnostic methods for detecting or prognosing diseases, disorders, damage or injury, associated with alterations of the Stanniocalcin compositions of the invention, and to therapeutic methods for treating such diseases, disorders, damage or injury.

AN 2002:78715 USPATFULL
TI Stanniocalcin polynucleotides, polypeptides, and methods based thereon
IN Olsen, Henrik S., Gaithersburg, MD, UNITED STATES
Zhang, Ke-Zhou, Brussels, BELGIUM
Lindsberg, Perttu, Helsinki, FINLAND
Tatlisumak, Turgut, Helsinki, FINLAND
Kaste, Markku, Vantaa, FINLAND
Andersson, Leif C., Helsinki, FINLAND
PA Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)
PI US 2002042372 A1 20020411
AI US 2001-840989 A1 20010425 (9)
RLI Continuation-in-part of Ser. No. WO 2000-US29432, filed on 26 Oct 2000, UNKNOWN
PRAI US 1999-161740P 19991027 (60)
DT Utility
FS APPLICATION
LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
CLMN Number of Claims: 47
ECL Exemplary Claim: 1
DRWN 12 Drawing Page(s)
LN.CNT 9559
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 13 OF 23 USPATFULL

AB This invention provides methods of obtaining **vaccines** by use of non-stochastic methods of directed evolution (DirectEvolution.TM.). These methods include non-stochastic polynucleotide site-saturation mutagenesis (Gene Site Saturation Mutagenesis.TM.) and non-stochastic polynucleotide reassembly (GeneReassembly.TM.). Through use of the claimed methods, vectors can be obtained which exhibit increased efficacy for use as genetic **vaccines**. Vectors obtained by using the methods can have, for example, enhanced antigen expression, increased uptake into a cell, increased stability in a cell, ability to tailor an immune response, and the like.

AN 2002:297432 USPATFULL
TI Non-stochastic generation of genetic **vaccines**
IN Short, Jay M., Rancho Santa Fe, CA, United States
PA Diversa Corporation, San Diego, CA, United States (U.S. corporation)
PI US 6479258 B1 20021112
AI US 2000-495052 20000131 (9)
RLI Continuation-in-part of Ser. No. US 1999-276860, filed on 26 Mar 1999
Continuation-in-part of Ser. No. US 1999-246178, filed on 4 Feb 1999, now patented, Pat. No. US 6171820 Continuation-in-part of Ser. No. US 1998-185373, filed on 3 Nov 1998 Continuation-in-part of Ser. No. US 1996-760489, filed on 5 Dec 1996, now patented, Pat. No. US 5830696
PRAI US 1995-8311P 19951207 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Park, Hankyel T.
LREP Gray Cary Ware & Freidenrich LLP, Haile, Lisa A.
CLMN Number of Claims: 86
ECL Exemplary Claim: 1
DRWN 66 Drawing Figure(s); 61 Drawing Page(s)
LN.CNT 19213
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 14 OF 23 USPATFULL

AB An isolated and purified outer membrane protein of a Moraxella strain, particularly M. catarrhalis, has a molecular mass of about 200 kDa. The

about 200 kDa outer membrane protein as well as nucleic acid molecules encoding the same are useful in diagnostic applications and immunogenic compositions, particularly for in vivo administration to a host to confer protection against disease caused by a bacterial pathogen that produces the about 200 kDa outer membrane protein or produces a protein capable of inducing antibodies in a host specifically reactive with the about 200 kDa outer membrane protein.

AN 2002:216836 USPATFULL
TI High molecular weight major outer membrane protein of moraxella
IN Sasaki, Ken, Willowdale, CANADA
Harkness, Robin E., Willowdale, CANADA
Loosmore, Sheena M., Aurora, CANADA
Klein, Michel H., Willowdale, CANADA
PA Aventis Pasteur Limited, Toronto, CANADA (non-U.S. corporation)
PI US 6440424 B1 20020827
AI US 1995-483855 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1995-431718, filed on 1 May 1995,
now patented, Pat. No. US 6335018
DT Utility
FS GRANTED
EXNAM Primary Examiner: Minnifield, Nita
LREP Sim & McBurney
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 18 Drawing Figure(s); 17 Drawing Page(s)
LN.CNT 1408
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 15 OF 23 USPATFULL

AB An isolated and purified outer membrane protein of a Moraxella strain, particularly M. catarrhalis, has a molecular mass of about 200 kDa. The about 200 kDa outer membrane protein as well as nucleic acid molecules encoding the same are useful in diagnostic applications and immunogenic compositions, particularly for in vivo administration to a host to confer protection against disease caused by a bacterial pathogen that produces the about 200 kDa outer membrane protein or produces a protein capable of inducing antibodies in a host specifically reactive with the about 200 kDa outer membrane protein.

AN 2002:931 USPATFULL
TI High molecular weight major outer membrane protein of moraxella
IN Sasaki, Ken, Willowdale, CANADA
Harkness, Robin E., Willowdale, CANADA
Klein, Michel H., Willowdale, CANADA
PA Aventis Pasteur Limited, Toronto, CANADA (non-U.S. corporation)
PI US 6335018 B1 20020101
AI US 1995-431718 19950501 (8)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Minnifield, Nita
LREP Sim & McBurney
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 5 Drawing Figure(s); 17 Drawing Page(s)
LN.CNT 1398
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 16 OF 23 USPATFULL

AB An isolated and purified outer membrane protein of a Moraxella strain, particularly M. catarrhalis, having a molecular mass of about 200 kDa, is provided. The about 200 kDa outer membrane protein as well as nucleic acid molecules encoding the same are useful in diagnostic applications and immunogenic compositions, particularly for in vivo administration to a host to confer protection against disease caused by a bacterial pathogen that produces the about 200 kDa outer membrane protein or

produces a protein capable of inducing antibodies in a host specifically reactive with the about 200 kDa outer membrane protein.

AN 2001:134223 USPATFULL
TI HIGH MOLECULAR WEIGHT MAJOR OUTER MEMBRANE PROTEIN OF MORAXELLA
IN SASAKI, KEN, WILLOWDALE, Canada
HARKNESS, ROBIN E., WILLOWDALE, Canada
LOOSMORE, SHEENA M., AURORA, Canada
CHONG, PELE, RICHMOND HILL, Canada
KLEIN, MICHEL H., WILLOWDALE, Canada
PI US 2001014672 A1 20010816
US 6448386 B2 20020910
AI US 1998-945567 A1 19980319 (8)
WO 1996-CA264 19960429
None PCT 102(e) date
PRAI US 1995-8431718 19950501
US 1995-8478370 19950607
US 1996-8621944 19960320
DT Utility
FS APPLICATION
LREP SIM & MCBURNEY, 6TH FLOOR, 330 UNIVERSITY AVENUE, TORONTO ONTARIO
CLMN Number of Claims: 37
ECL Exemplary Claim: 1
DRWN 47 Drawing Page(s)
LN.CNT 1689
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 17 OF 23 USPATFULL

AB Immunogenic conjugate molecules comprising at least a portion of a capsular polysaccharide of a **Streptococcus** strain linked to at least a portion of an outer membrane protein of a Haemophilus strain are provided in which the immunogenicity of the capsular polysaccharide is increased. Particularly capsular polysaccharide from **Streptococcus pneumoniae** are linked to an outer membrane protein of a Haemophilus influenzae strain, which protein may be the P1, P2 or particularly the P6 outer membrane protein. Conjugate molecules comprising the P6 protein linked to a capsular polysaccharide from an encapsulated pathogen other than **Streptococcus** also are described, in which the immunogenicity of the capsular polysaccharide is enhanced. Such conjugate molecules may be incorporated into immunogenic compositions for protecting a host against disease caused by the **Streptococcus** strain and preferably also the Haemophilus strain. The conjugate molecules and antibodies specific for the capsular polysaccharide or specific for the outer membrane protein may be employed in diagnostic procedures and kits. A process for individually isolating P1, P2 and P6 outer membrane proteins from a Haemophilus strain also is provided.

AN 2001:226761 USPATFULL
TI Immunogenic conjugate molecules
IN Yang, Yan-Ping, Willowdale, Canada
Kandil, Ali, Willowdale, Canada
Gisonni, Lucy, Toronto, Canada
Fahim, Raafat Emil Fahmy, Mississauga, Canada
Klein, Michel Henri, Willowdale, Canada
PA Aventis Pasteur Limited, Toronto, Canada (non-U.S. corporation)
PI US 6329512 B1 20011211
AI US 1995-467883 19950606 (8)
RLI Continuation of Ser. No. US 1995-371965, filed on 12 Jan 1995, now patented, Pat. No. US 5681570
DT Utility
FS GRANTED
EXNAM Primary Examiner: Graser, Jennifer
LREP Sim & McBurney
CLMN Number of Claims: 18
ECL Exemplary Claim: 1

DRWN 8 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 1509
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 18 OF 23 USPATFULL

AB Disclosed are the dbp gene and dbp-derived nucleic acid segments from *Borrelia burgdorferi*, the etiological agent of Lyme disease, and DNA segments encoding dbp from related borrelias. Also disclosed are decorin binding protein compositions and methods of use. The DBP protein and antigenic epitopes derived therefrom are contemplated for use in the treatment of pathological *Borrelia* infections, and in particular, for use in the prevention of bacterial adhesion to decorin. DNA segments encoding these proteins and anti-(decorin binding protein) antibodies will also be of use in various screening, diagnostic and therapeutic applications including active and passive immunization and methods for the prevention of *Borrelia* colonization in an animal. These DNA segments and the peptides derived therefrom are contemplated for use in the preparation of **vaccines** and, also, for use as carrier proteins in **vaccine** formulations, and in the formulation of compositions for use in the prevention of Lyme disease.

AN 2001:67646 USPATFULL

TI Decorin binding protein compositions

IN Guo, Betty, Houston, TX, United States

Hook, Magnus, Houston, TX, United States

PA The Texas A & M University System, College Station, TX, United States
(U.S. corporation)

PI US 6228835 B1 20010508

AI US 1998-221938 19981228 (9)

RLI Division of Ser. No. US 1996-589711, filed on 22 Jan 1996, now patented,
Pat. No. US 5853987, issued on 29 Dec 1998 Continuation-in-part of Ser.
No. US 1995-427023, filed on 24 Apr 1995, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Zitomer, Stephanie W.

LREP Williams, Morgan and Amerson

CLMN Number of Claims: 24

ECL Exemplary Claim: 1

DRWN 25 Drawing Figure(s); 14 Drawing Page(s)

LN.CNT 4504

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 19 OF 23 USPATFULL

AB Immunogenic conjugate molecules comprising at least a portion of a capsular polysaccharide of a **Streptococcus** strain linked to at least a portion of an outer membrane protein of a *Haemophilus* strain are provided in which the immunogenicity of the capsular polysaccharide is increased. Particularly capsular polysaccharide from **Streptococcus pneumoniae** are linked to an outer membrane protein of a *Haemophilus influenzae* strain, which protein may be the P1, P2 or particularly the P6 outer membrane protein. Conjugate molecules comprising the P6 protein linked to a capsular polysaccharide from an encapsulated pathogen other than **Streptococcus** also are described, in which the immunogenicity of the capsular polysaccharide is enhanced. Such conjugate molecules may be incorporated into immunogenic compositions for protecting a host against disease caused by the **Streptococcus** strain and preferably also the *Haemophilus* strain. The conjugate molecules and antibodies specific for the capsular polysaccharide or specific for the outer membrane protein may be employed in diagnostic procedures and kits. A process for individually isolating P1, P2 and P6 outer membrane proteins from a *Haemophilus* strain also is provided.

AN 2001:10547 USPATFULL

TI Generation of immune response using immunogenic conjugate of molecules

IN Yang, Yan-ping, Willowdale, Canada

Kandil, Ali, Willowdale, Canada
Gisonni, Lucy, Toronto, Canada
Fahmy, Raafat Emil Fahmy, Mississauga, Canada
Klein, Michel Henri, Willowdale, Canada
PA Connaught Laboratories Limited, North York, Canada (non-U.S.
corporation)
PI US 6177085 B1 20010123
AI US 1995-467884 19950606 (8)
RLI Continuation of Ser. No. US 1995-371965, filed on 12 Jan 1995, now
patented, Pat. No. US 5681570
DT Utility
FS Granted
EXNAM Primary Examiner: Smith, Lynette R. F.; Assistant Examiner: Devi, S.
LREP Sim & McBurney
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN 8 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 1388
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 20 OF 23 USPATFULL

AB An isolated and purified non-denatured outer membrane protein CD which
is that of or corresponds to that isolatable from a Branhamella strain,
particularly B. catarrhalis, is isolated from a bacterial strain by
fractionating a cell lysate formed by disrupting a cell mass of the
bacterial strain by centrifugation to provide a pellet and a discard
supernatant containing a large proportion of soluble bacterial proteins.
The pellet is selectively extracted to remove the remaining soluble
proteins, the membrane proteins other than CD and other contaminants
such as lipopolysaccharide and phospholipids. The remaining
CD-containing pellet is dispersed and solubilized and then fractionated
by centrifugation to remove the remaining cell debris. The CD protein is
useful in diagnostic applications and immunogenic compositions,
particularly for in vivo administration to a host to confer protection
against disease caused by a bacterial pathogen that produces CD protein
or produces a protein capable of inducing antibodies in a host
specifically reactive with CD protein.

AN 2000:125203 USPATFULL

TI Major outer membrane protein CD of branhamella
IN Yang, Yan-Ping, Willowdale, Canada
Harkness, Robin Edmond, Willowdale, Canada
Myers, Lisa Elizabeth, Guelph, Canada
McGuiness, Ursula, Richmond Hill, Canada
Klein, Michel Henri, Willowdale, Canada

PA Connaught Laboratories Limited, North York, Canada (non-U.S.
corporation)

PI US 6121427 20000919
AI US 1995-474394 19950607 (8)
RLI Continuation of Ser. No. US 1994-328589, filed on 24 Oct 1994, now
abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Minnifield, Nita
LREP Sim & McBurney
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 8 Drawing Figure(s); 7 Drawing Page(s)
LN.CNT 1108
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 21 OF 23 USPATFULL

AB Disclosed are the dbp gene and dbp-derived nucleic acid segments from
Borrelia burgdorferi, the etiological agent of Lyme disease, and DNA
segments encoding dbp from related borrelias. Also disclosed are decorin

binding protein compositions and methods of use. The DBP protein and antigenic epitopes derived therefrom are contemplated for use in the treatment of pathological Borrelia infections, and in particular, for use in the prevention of bacterial adhesion to decorin. DNA segments encoding these proteins and anti-(decorin binding protein) antibodies will also be of use in various screening, diagnostic and therapeutic applications including active and passive immunization and methods for the prevention of Borrelia colonization in an animal. These DNA segments and the peptides derived therefrom are contemplated for use in the preparation of vaccines and, also, for use as carrier proteins in vaccine formulations, and in the formulation of compositions for use in the prevention of Lyme disease.

AN 1998:162259 USPTFULL
TI Decorin binding protein compositions and methods of use
IN Guo, Betty, Houston, TX, United States
Hook, Magnus, Houston, TX, United States
PA The Texas A & M University System, College Station, TX, United States (U.S. corporation)
PI US 5853987 19981229
AI US 1996-589711 19960122 (8)
RLI Continuation-in-part of Ser. No. US 1995-427023, filed on 24 Apr 1995, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Horlick, Kenneth R.; Assistant Examiner: Tung, Joyce
LREP Arnold, White & Durkee
CLMN Number of Claims: 68
ECL Exemplary Claim: 1
DRWN 25 Drawing Figure(s); 14 Drawing Page(s)
LN.CNT 4684
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 22 OF 23 USPTFULL

AB An isolated and purified outer membrane protein of a Moraxella strain, particularly M. catarrhalis, has a molecular mass of about 200 kDa. The about 200 kDa outer membrane protein as well as nucleic acid molecules encoding the same are useful in diagnostic applications and immunogenic compositions, particularly for in vivo administration to a host to confer protection against disease caused by a bacterial pathogen that produces the about 200 kDa outer membrane protein or produces a protein capable of inducing antibodies in a host specifically reactive with the about 200 kDa outer membrane protein.

AN 1998:112095 USPTFULL
TI Nucleic acids encoding high molecular weight major outer membrane protein of moraxella
IN Sasaki, Ken, 1131 Steeles Avenue, West, Apt. No. 512, Willowdale, Ontario, Canada M2R 3W8
Harkness, Robin E., 640 Sheppard Avenue, East, Apt. #1706, Willowdale, Ontario, Canada M2K 1B8
Loosmore, Sheena M., 70 Crawford Rose Drive, Aurora, Ontario, Canada L4G 4R4
Klein, Michel H., 16 Munro Boulevard, Willowdale, Ontario, Canada M2P 1B9
PI US 5808024 19980915
AI US 1995-478370 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1995-431718, filed on 1 May 1995
DT Utility
FS Granted
EXNAM Primary Examiner: Walsh, Stephen; Assistant Examiner: Sorensen, Kenneth A.
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 18 Drawing Figure(s); 17 Drawing Page(s)
LN.CNT 1481

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 23 OF 23 USPATFULL

AB Immunogenic conjugate molecules comprising at least a portion of a capsular polysaccharide of a **Streptococcus** strain linked to at least a portion of an outer membrane protein of a Haemophilus strain are provided in which the immunogenicity of the capsular polysaccharide is increased. Particularly capsular polysaccharide from **Streptococcus pneumoniae** are linked to an outer membrane protein of a Haemophilus influenzae strain, which protein may be the P1, P2 or particularly the P6 outer membrane protein. Conjugate molecules comprising the P6 protein linked to a capsular polysaccharide from an encapsulated pathogen other than **Streptococcus** also are described, in which the immunogenicity of the capsular polysaccharide is enhanced. Such conjugate molecules may be incorporated into immunogenic compositions for protecting a host against disease caused by the **Streptococcus** strain and preferably also the Haemophilus strain. The conjugate molecules and antibodies specific for the capsular polysaccharide or specific for the outer membrane protein may be employed in diagnostic procedures and kits. A process for individually isolating P1, P2 and P6 outer membrane proteins from a Haemophilus strain also is provided.

AN 97:99026 USPATFULL

TI Immunogenic conjugate molecules

IN Yang, Yan-ping, Willowdale, Canada

Kandil, Ali, Willowdale, Canada

Gisonni, Lucy, Toronto, Canada

Fahim, Raafat Emil Fahmy, Mississauga, Canada

Klein, Michel Henri, Willowdale, Canada

PA Connaught Laboratories Limited, North York, Canada (non-U.S. corporation)

PI US 5681570 19971028

AI US 1995-371965 19950112 (8)

DT Utility

FS Granted

EXNAM Primary Examiner: Housel, James C.; Assistant Examiner: Shaver, Jennifer

CLMN Number of Claims: 3

ECL Exemplary Claim: 1

DRWN 8 Drawing Figure(s); 5 Drawing Page(s)

LN.CNT 1377

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

FULL ESTIMATED COST

ENTRY

SESSION

55.82

74.81

STN INTERNATIONAL LOGOFF AT 14:03:10 ON 31 MAR 2003